sarepta srpt - Search News

News

Sarepta to continue Elevidys shipments

Yahoo Finance · 47m

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement:

Reuters on MSN · 14m

Sarepta to pause gene therapy Elevidys shipments in US

Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatment died.

Seeking Alpha on MSN · 14h

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second session after plunging 36% on Friday.

FDA Shuts Down Sarepta Gene Therapy Trials

Zacks Investment Research on M… · 9h

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non-ambulant (unable to walk) limb-girdle muscular dystrophy (LGMD) patient died due to acute liver failure (ALF).

MarketWatch · 12h

FDA Places Sarepta's Investigational Gene-Therapy Trials on Hold Following Patient Death

The Food and Drug Administration placed a clinical hold on Sarepta Therapeutics' investigational gene-therapy clinical trials for limb-girdle muscular dystrophy, a group of genetic disorders that cause muscles to weaken and atrophy.

MyChesCo on MSN · 6h

FDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver Failure

The U.S. Food and Drug Administration on Friday placed Sarepta Therapeutics’ gene therapy trials for limb girdle muscular dystrophy on clinical hold following the deaths of three patients

11h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

7h

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

6hon MSN

Sarepta shares cut to $0 at H.C. Wainwright

H.C. Wainwright has taken the unusual step of setting a $0 price target for troubled biotech Sarepta Therapeutics ...

15hon MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...

4d

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results